1. Home
  2. OFG vs NTLA Comparison

OFG vs NTLA Comparison

Compare OFG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFG Bancorp

OFG

OFG Bancorp

HOLD

Current Price

$43.07

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$8.84

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFG
NTLA
Founded
1964
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
986.9M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
OFG
NTLA
Price
$43.07
$8.84
Analyst Decision
Buy
Buy
Analyst Count
4
22
Target Price
$45.75
$19.83
AVG Volume (30 Days)
249.6K
4.0M
Earning Date
01-21-2026
11-06-2025
Dividend Yield
2.81%
N/A
EPS Growth
6.55
N/A
EPS
4.40
N/A
Revenue
$624,004,000.00
$57,528,000.00
Revenue This Year
N/A
$1.96
Revenue Next Year
$1.09
N/A
P/E Ratio
$9.69
N/A
Revenue Growth
N/A
33.52
52 Week Low
$33.15
$5.90
52 Week High
$46.11
$28.25

Technical Indicators

Market Signals
Indicator
OFG
NTLA
Relative Strength Index (RSI) 69.21 40.31
Support Level $41.88 $8.90
Resistance Level $42.67 $9.55
Average True Range (ATR) 0.72 0.55
MACD 0.29 0.29
Stochastic Oscillator 94.48 45.84

Price Performance

Historical Comparison
OFG
NTLA

About OFG OFG Bancorp

OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: